Announcements Trials
Browse Landscape

Phase

Phase NA 25Phase 2 9Phase EARLY_PHASE1 2Phase 3 2Phase 1 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Cervical Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Sentinel Lymph Node Biopsy × Clear all
NCT05981014 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2 Recruiting
196 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡